SherwynLSchwartzMD

Endocrinology • San Antonio, TX

Diabetes, Lipid Metabolism

Endocrinologist

Join to view full profile

Dr. Schwartz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Schwartz's full profile

Already have an account?

Office
8042 wurzbach suite 420
San Antonio, TX 78229
Phone+1 210-949-0807
Is this information wrong?

Education & Training

Rush University Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1976 - 1977
Michael Reese Hospital and Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1975 - 1976
Michael Reese Hospital and Medical CenterResidency, Internal Medicine, 1972 - 1975
University of Illinois College of MedicineClass of 1972

Certifications & Licensure

IL State Medical License 1973 - Present
CA State Medical License 1977 - Present
TX State Medical License 1977 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com
Top MD Consumers Checkbook

Clinical Trials

Safety and Efficacy of PEG-Encapsulated Islet Allografts Implanted in Type I Diabetic Recipients Start of enrollment: 2005 Nov 01
Terminated
Phase 1, Phase 2
The Effect of Betahistine on Body Weight in Obese Subjects Start of enrollment: 2007 Jan 01
Completed
Phase 2
Safety and Tolerability Study of MBX-2044 in Patients With Type 2 Diabetes Start of enrollment: 2006 Oct 01
Completed
Phase 2
A Prospective, Randomized, Parallel Crossover Study Demonstrating Subject Wearability and Usability of the I-Port Injection Port Start of enrollment: 2006 Oct 01
Completed
Not Applicable
A Phase 2b Study of DIO-902 or DIO-902 Placebo in Addition to Metformin and Atorvastatin or Atorvastatin Placebo for Type 2 Diabetes Start of enrollment: 2007 Jul 01
Terminated
Phase 2
A Study to Evaluate the Effect of Nasal Insulin on Postprandial Glycemic Control in Type 2 Diabetic Patients Start of enrollment: 2008 Mar 01
Completed
Phase 2
Pharmacokinetic Study of Oral Testosterone (T) Ester Formulations in Hypogonadal Men Start of enrollment: 2008 Jun 01
Completed
Phase 2
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data Start of enrollment: 2013 Nov 26
Completed
Not Applicable
Appearance of Plasma Amino Acids Following Consumption of an Oral Nutrition Supplement Start of enrollment: 2016 Feb 01
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

Non-alcoholic Steatohepatitis: From Pathophysiology to Clinical Practice
Sherwyn Schwartz, Jean Lucas, Mark H DeLegge, Iqvia, Raleigh, Nc, Usa> ;Touchreviews in Endocrinology. 2021 Jan 1
Plasma glucose and insulin response to two oral nutrition supplements in adults with type 2 diabetes mellitus.
Maureen B. Huhmann, Kristen N Smith, Sherwyn L Schwartz, Stacie K Haller, Sarah R. Irvin, Sarah S. Cohen> ;BMJ Open Diabetes Research & Care. 2016 Aug 1
27 citations
A pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathy.
Sherwyn Schwartz, Mila Etropolski, Douglas Y. Shapiro, C. Rauschkolb, Aaron I. Vinik, Bernd Lange, Kimberly Cooper, Ilse Van Hove, Juergen Haeussler> ;Clinical Drug Investigation. 2015 Feb 1
Use of incretin-based therapy in hospitalized patients with hyperglycemia.
Umpierrez GE, Schwartz S> ;Endocr Pract. 2014-09-01
59 citations
Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in pati...
Sherwyn Schwartz, Bola Akinlade, Sally Klasen, Donna Kowalski, Wenhui Zhang, Wim Wilpshaar> ;Diabetes Technology & Therapeutics. 2011 Nov 30
Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.
Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu C, Lash J, Leonard M, Ku...> ;JAMA. 2011-06-15
Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes.
> ;Diabetes Obes Metab. 2011 Sep
6 citations
A Dose-Ranging Study of the DPP-IV Inhibitor PF-734200 Added to Metformin in Subjects With Type 2 Diabetes*.
Steven G. Terra, V. Somayaji, S. Schwartz, A. J. Lewin, J. G. Teeter, Haiqing Dai, Tu T. Nguyen, R. A. Calle> ;Experimental and Clinical Endocrinology & Diabetes. 2011 Apr 6
161 citations
Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial
Sherwyn Schwartz, Mila Etropolski, D.Y. Shapiro, Akiko Okamoto, Robert Lange, Juergen Haeussler, Christine Rauschkolb> ;Current Medical Research and Opinion. 2010 Dec 17
4 citations
Humalog(®) KwikPen™: an insulin-injecting pen designed for ease of use.
Sherwyn L. Schwartz, Debra A. Ignaut, Jennifer N Bodie> ;Expert Review of Medical Devices. 2010 Nov 1
51 citations
Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors.
Sherwyn L. Schwartz> ;American Journal of Geriatric Pharmacotherapy. 2010 Oct 1
10 citations
Insulin pharmacokinetics following dosing with Technosphere insulin in subjects with chronic obstructive pulmonary disease.
Elizabeth Potocka, Nikhil Amin, James P. Cassidy, Sherwyn Schwartz, Madison Gray, Peter Richardson, Robert A. Baughman> ;Current Medical Research and Opinion. 2010 Sep 15
6 citations
Correct use of a new reusable insulin injection pen by patients with diabetes: a design validation study.
Sherwyn Schwartz> ;Journal of diabetes science and technology. 2010 Sep 1
4 citations
Evaluation of the potential for pharmacokinetic and pharmacodynamic interactions between dutogliptin, a novel DPP4 inhibitor, and metformin, in type 2 diabetic patients.
Jianke Li, Kirsti Klemm, A. Marie O'Farrell, Hans-Peter Guler, Julie M. Cherrington, Sherwyn Schwartz, Teresa Boyea> ;Current Medical Research and Opinion. 2010 Jul 15
8 citations
Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes
Yan-Ling He, Jessica V. Valencia, Yiming Zhang, Sherwyn Schwartz, Monica Ligueros-Saylan, James E. Foley, William P. Dole> ;British Journal of Clinical Pharmacology. 2010 Jul 1
27 citations
IMPROVED GLYCEMIC CONTROL WITH INSULIN GLARGINE VERSUS PIOGLITAZONE AS ADD-ON THERAPY TO SULFONYLUREA OR METFORMIN IN PATIENTS WITH UNCONTROLLED TYPE 2 DIABETES MELLITUS
Luigi F. Meneghini, Louise Traylor, Sherwyn L. Schwartz> ;Endocrine Practice. 2010 Mar 29
Comparative device assessments: Humalog KwikPen compared with vial and syringe and FlexPen.
Ignaut, D. A., Ignaut, D. A., Schwartz, S. L., Schwartz, S. L., Sarwat, S., Sarwat, S., Murphy, H. L., Murphy, H. L.> ;The Diabetes educator. 2009 Sep 29
36 citations
Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insul...
Philip Raskin, G. Matfin, Sherwyn Schwartz, L. Chaykin, P. L. Chu, R. Braceras, A. Wynne> ;Diabetes, Obesity and Metabolism. 2009 Jan 1
15 citations
United States patient preference and usability for the new disposable insulin device Solostar versus other disposable pens.
Jerome S. Fischer, Steven V. Edelman, Sherwyn Schwartz> ;Journal of diabetes science and technology. 2008 Nov 1
7 citations
Validation of the SoloSTAR insulin pen.
Sherwyn Schwartz, Aleksandra Vlajnic> ;Diabetes Technology & Therapeutics. 2008 Aug 21
41 citations
Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria
Hiddo J.L. Heerspink, Tom Greene, Julia B. Lewis, Itamar Raz, Richard D. Rohde, Lawrence G. Hunsicker, Sherwyn L. Schwartz, Stephen Aronoff, Murray A. Katz, Gilbert M....> ;Nephrology Dialysis Transplantation. 2008 Jun 1
33 citations
Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus.
Ying Hong, Shashank Rohatagi, Bahru Habtemariam, Joseph R. Walker, Sherwyn L. Schwartz, Donald E. Mager> ;The Journal of Clinical Pharmacology. 2008 Jun 1
15 citations
Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicent...
Andrew J. Lewin, Robert Lipetz, Jacqueline Wu, Sherwyn Schwartz> ;Clinical Therapeutics. 2007 May 1
143 citations
Accuracy of the 5-day freestyle navigator continuous glucose monitoring system : Comparison with frequent laboratory reference measurements
Richard L. Weinstein, Sherwyn Schwartz, Ronald L. Brazg, Jolyon Robert Bugler, Thomas A. Peyser, Geoffrey V. McGarraugh> ;Diabetes Care. 2007 May 1
158 citations
Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydroc...
Franklin J. Zieve, Marcia F. Kalin, Sherwyn Schwartz, Michael R. Jones, William L. Bailey> ;Clinical Therapeutics. 2007 Jan 1
Join now to see all

Press Mentions

Effect of Alendronate and MK-677 (A Growth Hormone Secretagogue), Individually and in Combination, on Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporotic WomenJuly 22nd, 2020
How a New COVID Vaccine Type Could Eliminate the Need for BoostersNovember 23rd, 2022
More San Antonio Hispanics Need to Participate in Coronavirus Vaccine Trials, Officials UrgeDecember 7th, 2020